Abstract: Specialized high-protein, reduced-carbohydrate edible food products with excellent organoleptic and stability characteristics can be produced which modulate or reduce insulin resistance and increase fat-free mass in a calorie-restricted dietary regimen. These specialized food products, ranging from breads, pasta, pizza dough, tortillas, bagels, pastries, and other similar food products higher in protein and lower in carbohydrate content, have a significant clinical benefit. Modulation or reduction of insulin resistance using such food products has been observed to be clinically relevant and can be used for the treatment of many chronic disease conditions associated with increased insulin resistance.

Abstract: The invention relates to compositions and methods for reducing chronic low-level inflammation associated with chronic conditions. Specifically, the invention relates to compositions of hydrophobic derivatives of aspirin and/or hydrophobic derivatives of sesamol in combination with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and their methods for reducing chronic low-level inflammation associated with chronic conditions including obesity, metabolic syndrome, diabetes, cardiovascular disease, cancer, auto-immune disorders, ocular and neurological disorders in a mammal.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: The invention relates to a novel class of inhibitor of arachidonic acid useful for treating inflammatory conditions. Specifically, the invention relates to hydrophobic and hydrophilic derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Abstract: A method and nutritional and pharmaceutical compositions are provided for the reduction of hyperinsulinemia and the improvement of disease conditions related to hyperinsulinemia by administering a nutritional composition to modify hormonal response.

Abstract: The modulation of prostaglandin levels can be realized through the dietary intake of specified ratios of activated Omega 6 essentially fatty acids when combined with the appropriate amount of eicosapentaenoic acid (EPA), an Omega 3 fatty acid. The modulation of prostaglandins levels can be determined by changes in physiological parameters which are related to prostaglandin levels in mammals. Certain ratios of activated Omega 6 essentially fatty acids and EPA can have significant physiological benefits, whereas other ratios demonstrate detrimental physiological effects in mammals.

Abstract: Synthetic phospholipid compounds and their method of preparation, which compounds are phosphatidylethanolamine polycarboxyl polyalkylene glycols and are prepared by the reaction of a phosphatidylethanolamine, a polycarboxylic acid, such as succinic or glutaryl anhydride, and a polyalkylene glycol, such as polyethylene glycol.

Abstract: Liquid magnetic compositions suitable for use in coating a substrate, such as a tape or a disc, for the preparation of magnetic memory devices, which liquid composition comprises finely-divided magnetic particles, optionally a binder for the magnetic particles, a dispersing agent for the magnetic particles and a volatile liquid solvent, the dispersing agent comprising a synthetic phosphatidyl ethanolamine polymer.

Abstract: Novel synthetic phospholipid compounds, the compounds having the structural formula: ##STR1## where X is a hydrogen or alkyl group, n can vary from about 0 to 200, m can vary from 2 to 10, and R.sub.1 and R.sub.2 are saturated or unsaturated acyl radicals.

Abstract: A method of emulsifying water insoluble compounds particularly cholesterol, cholesterol esters and triglycerides in the blood which method comprises emulsifying the water insoluble compound with a novel synthetic phosphatidyl quaternary ammonium, sulfonium and phosphonium hydroxide compounds or emulsifying agents which compounds have a hydrophobic/hydrophilic balance different from the natural phosphatidylcholine, by changes in the polar group.

Abstract: A kit for determining the level of LDL cholesterol in body fluids is disclosed which contains a plant lectin which is a specific agglutinating agent for LDL.

Abstract: A method of preparing a controlled-release pharmaceutical compound for oral administration, which pharmaceutical compound is subject to enzymatic hydrolysis on oral administration, which method comprises encapsulating the pharmaceutical compound with a synthetic phosphatidyl compound having a modified polarhead moiety which increases the resistance of the phosphatidyl compound to phospholipase C hydrolysis.

Abstract: A method for determining the level of LDL cholesterol in blood plasma wherein LDL cholesterol is separated from other soluble cholesterol fractions by selectively agglutinating LDL with a plant lectin and subsequently detecting the amount of cholesterol associated with agglutinated LDL.

Abstract: Novel synthetic phosphatidyl phosphonium hydroxide compounds are prepared which have a hydrophobic/hydrophilic balance different from the natural phosphatidylcholine, which alterations are carried out by changes in the quaternary phosphonium polar group to provide different surfactant properties.

Abstract: Novel synthetic phosphatidyl ammonium hydroxide compounds are prepared which have a hydrophobic/hydrophilic balance different from the natural phosphatidylcholine, which alterations are carried out by changes in the quaternary ammonium polar group to provide different surfactant properties.

Abstract: A method of preparing a controlled-release pharmaceutical compound for oral administration, which pharmaceutical compound is subject to enzymatic hydrolysis on oral administration, which method comprises encapsulating the pharmaceutical compound with a synthetic phosphatidyl compound having a modified polarhead moiety which increases the resistance of the phosphatidyl compound to phospholipase C hydrolysis.